Group 1 - The core point of the article is that Fosun Yalifeng (Dalian) Biopharmaceutical Co., Ltd. has initiated a Phase I clinical trial to evaluate the safety of a lyophilized human rabies vaccine (human diploid cells) using two immunization schedules for individuals aged 10 to 60 years [1][2] - The clinical trial is registered under the number CTR20253875, with the first public information date set for September 24, 2025 [1] - The vaccine is administered via intramuscular injection in the deltoid muscle, with a dosage of 1.0 mL per person [1] Group 2 - The primary endpoints of the trial include the incidence of adverse events within 30 minutes post-injection, the incidence of solicited adverse events within 0-7 days post-injection, and the incidence of all adverse reactions within 30 days after the first dose [2] - The trial is currently ongoing and has not yet started recruiting participants, with a target enrollment of 80 individuals [3]
复星雅立峰冻干人用狂犬病疫苗（人二倍体细胞）启动I期临床 适应症为狂犬病
Xin Lang Cai Jing·2025-09-24 05:16